Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
October 28 2022 - 7:32AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of October 2022
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 28 October 2022, London UK
GSK marketing authorisation application for respiratory syncytial
virus older adult vaccine candidate accepted by European Medicines
Agency under accelerated assessment
●
Application based on positive
pivotal phase III data showing vaccine
efficacy against respiratory
syncytial virus-lower respiratory tract disease in
adults aged 60 years and above with a favourable safety
profile
●
This
is the second major regulatory milestone for the vaccine candidate
following acceptance of a submission in Japan
GSK plc (LSE/NYSE: GSK) today announced that the European Medicines
Agency (EMA) has validated the marketing authorisation application
(MAA) for its respiratory syncytial virus (RSV) older adult vaccine
candidate.
MAAs may be eligible for accelerated assessment if
the EMA's Committee for Medicinal Products for Human Use
decides the product is of major interest for public health and
therapeutic innovation. A
European regulatory decision is anticipated in Q3 2023. If
approved, GSK's RSV older adult vaccine candidate has the potential
to be the first vaccine available to help protect older adults from
RSV lower respiratory tract disease (LRTD).
The MAA is based on positive data from a prespecified interim
analysis of the pivotal AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial, which showed high overall
vaccine efficacy against RSV LRTD in adults aged 60 years and
above. The vaccine was well tolerated with a favourable safety
profile. The most frequent observed solicited adverse events were
injection site pain, fatigue, myalgia, and headache. Consistent
high vaccine efficacy was observed against LRTD in severe disease,
adults aged 70-79 years, adults with underlying comorbidities and
across RSV A and B strains.
This is the second major regulatory development for GSK's RSV older
adult vaccine candidate following Japanese regulatory submission
acceptance in October 2022. GSK's
RSV older adult vaccine candidate contains a recombinant subunit
prefusion RSV F glycoprotein antigen (RSVPreF3) combined with GSK's
proprietary AS01E adjuvant. There
are currently no RSV vaccines for older adults approved anywhere in
the world.
About the AReSVi-006 trial
The
AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial is a randomised,
placebo-controlled, observer-blind, multi-country trial to
demonstrate the efficacy of a single dose of GSK's adjuvanted
RSVPreF3 older adult investigational vaccine in adults aged 60
years and above. Approximately 25,000 participants were enrolled
from 17 countries.
The GSK
proprietary AS01 adjuvant system contains QS-21 Stimulon adjuvant
licensed from Antigenics Inc, a wholly owned subsidiary of Agenus
Inc.
About RSV in adults
RSV is a common contagious virus affecting the lungs and breathing
passages. It is one of the major remaining infectious diseases for
which there is currently no vaccine or specific treatment available
for adults. In adults, RSV infection is typically mild, but may
lead to severe outcomes. Older
adults are at high risk for severe disease due to age-related
decline in immunity and underlying conditions. RSV can exacerbate
conditions, including chronic obstructive pulmonary disease, asthma
and chronic heart failure and can lead to severe outcomes, such as
pneumonia, hospitalisation, and death. Each year, RSV causes over
420,000 hospitalisations and 29,000 deaths in adults aged 60 years
and above in industrialised countries. Adults with underlying
conditions are more likely to seek medical advice and have higher
hospitalisation rates than adults without these
conditions.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com/company.
GSK enquiries
|
|
|
|
Media:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
Simon
Moore
|
+44 (0)
20 8047 5502
|
(London)
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
Alison
Hunt
|
+1 540
742 3391
|
(Washington
DC)
|
|
|
|
|
Investor
Relations:
|
Nick
Stone
|
+44 (0)
7717 618834
|
(London)
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
Josh
Williams
|
+44 (0)
7385 415719
|
(London)
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
Frannie
DeFranco
|
+1 215
751 4855
|
(Philadelphia)
|
|
|
|
|
Cautionary statement regarding forward-looking
statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2021, GSK's Q2 Results for 2022 and
any impacts of the COVID-19 pandemic.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GSK plc
|
|
(Registrant)
|
|
|
Date: October
28, 2022
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GSK plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Jun 2024 to Jul 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Jul 2023 to Jul 2024